The clinical utility of gene testing for alzheimer's disease

Neurology International

Volumn 3, Issue 1, 2011, Pages 1-3

  Atkins, Emily R ^a   Panegyres, Peter K ^a  

^a Neurodegenerative Disorders Research   (Australia)

Author keywords

Alzheimer's disease; Gene testing

Indexed keywords

AMYLOID PRECURSOR PROTEIN; APOLIPOPROTEIN E4; CLATHRIN ASSEMBLY PROTEIN; CLUSTERIN; COMPLEMENT COMPONENT C3B RECEPTOR; PRESENILIN 1; PRESENILIN 2; SORTILIN;

ALZHEIMER DISEASE; ARTICLE; DIAGNOSTIC VALUE; FAMILIAL DISEASE; GENE MUTATION; GENETIC ASSOCIATION; GENETIC SCREENING; GENETIC SUSCEPTIBILITY; GENOTYPE; HUMAN; INCIDENCE; ONSET AGE; RISK FACTOR; SINGLE NUCLEOTIDE POLYMORPHISM;

EID: 80053070367     PISSN: 20358385     EISSN: 20358377     Source Type: Journal    
DOI: 10.4081/ni.2011.e1     Document Type: Article

References (29)

1. Alzheimer's Disease International. World Alzheimer Report. 2009; available from: http://www.alz.co.uk/research/worldreport/
2. Mayeux R. Early Alzheimer's disease. N Engl J Med 2010;362:2194-201.
3. Skotte N, et al. Genome-wide association studies identify new interesting loci for late-onset Alzheimer's disease. Clin Genet 2010; 77:330-2.
4. Panegyres PK, Goldblatt J, Walpole I, et al. Genetic testing for Alzheimer's disease. Med J Aust 2000;172:339-43.
5. Guerreiro RJ, Gustafson DR, Hardy J. The genetic architecture of Alzheimer's disease: Beyond APP, PSENs and APOE. Neurobiol Aging 2010 Jun 29. [Epub ahead of print]
6. Bettens K, Sleegers K, Van Broeckhoven C. Current status on Alzheimer disease molecular genetics: from past, to present, to future. Hum Mol Genet 2010;19:R4-R11.
7. Bertram L, Tanzi RE. Genome-wide association studies in Alzheimer's disease. Hum Mol Genet 2009;18:R137-R45.
8. Rogaeva E, Meng Y, Lee JH, et al. The neu-ronal sortilin-related receptor SORL1 is genetically associated with Alzheimer disease. Nat Genet 2007;39:168-77.
9. Wertz DC, Fletcher JC, Berg K. Review of ethical issues in medical genetics. World Health Organisation, 2003; available from: http://www.whoint/genomics/publica-tions/en/ethical_issuesin_medgenet-ics%20report.pdf
10. Verlinsky Y, Rechitsky S, Verlinsky O, et al. Preimplantation diagnosis for early-onset Alzheimer disease caused by V717L mutation. JAMA 2002;287:1018-21.
11. Bertram L, Lill CM, Tanzi RE. The genetics of Alzheimer disease: Back to the future. Neuron 2010;68:270-81.
12. Coon KD, Myers AJ, Craig DW, et al. A high-density whole-genome study reveals that APOE is the major susceptibility gene for sporadic late-onset Alzheimer's disease. J Clin Psychiatry 2007;68:613-18.
13. Harold D, Abraham R, Hollingworth P, et al. Genome-wide assocciation study identifies variants at CLU and PICALM associated with Alzheimer's disease. Nat Genet 2009;41:1088-93.
14. Lambert JC, Heath S, Even G, et al. Genome-wide association study identifies variants at CLU and CR1 associated with Alzheimer's disease. Nat Genet 2009;41: 1094-9.
15. Naj AC, Beecham GW, Martin ER, et al. Dementia revealed: Novel chromosome 6 locus for late-onset Alzheimer disease provides genetic evidence for folate-pathway abnormalities. PLoS Genet 2010;6: e10011130.
16. Reiman EM, Webster JA, Myers AJ, et al. GAB2 alleles modify Alzheimer's risk in APOE epsilon4 carriers. Neuron 2007; 54:713-20.
17. Seshadri S, Fitzpatrick AL, Ikram MA, et al. Genome-wide analysis of genetic loci associated with Alzheimer disease. JAMA 2010;303:1832-40.
18. Holston EC, Schutte DL. The clinical utility of genetic information in the care of persons with Alzheimer's disease. Med -surg Nurs 2004;13:415-9.
19. Mayeux R, Saunders AM, Shea S, et al. Utility of the apoliprotein E genotype in the diagnosis of Alzheimer's disease. N Engl J Med 1998;338:506-511.
20. Dubois B, Feldman HH, Jacova C, et al. Research criteria for the diagnosis of Alzheimer's disease: revising the NINCDS-ADRDA criteria. Lancet Neurol 2007;6:734-46.
21. Hort J, O'Brien JT, Gainotti G, et al. EFNS guidelines for the diagnosis and management of Alzheimer's disease. Eur J Neurol 2010;17:1236-48.
22. Green RC, Roberts JS, Cupples LA, et al. Disclosure of APOE genotype for risk of Alzheimer's disease. N Engl J Med 2009; 361:245-54.
23. Chilibeck G, Lock M, Sehdev M. Postgenomics, uncertain futures, and the familiarization of susceptibility genes. Social Science and Medicine. 2010; DOI 10.1016/j.socscimed.2010.01.053.
24. World Health Organisation. Quality and safety in genetic testing: an emerging concern. 2010. Available from: http://www.who.int/genomics/policy/quali-ty_safety/en/print.html
25. National Center for Biotechnology Information (US). Questions and answers: genetic testing registry. 2010; available from: http://www.ncbi.nlm.nih.gov/gtr/qa/
26. Food and Drug Administration (US). Direct-to-consumer genetic testing and the consequences to the public. 2010. Available from: http://www.fda.gov/ NewsEvents/Testimony/ucm219925.htm
27. Government Accountability Office (US). Direct-to-consumer genetic tests: misleading test results are further complicated by deceptive marketing and other questionable practices. 2010; Available from: http://www. gao.gov/highlights/d10847thigh.pdf
28. MacArthur D. Sample swaps at 23andMe: a cautionary tale. Genetic Future 2010; Available from: http://scienceblogs.com/ geneticfuture/2010/06/sample_swaps_at_ 23andme_a_caut.php
29. Almqvist EW, Bloch M, Brinkman R, et al. A worldwide assessment of the frequency of suicide, suicide attempts, or psychiatric hospitalization after predictive testing for Huntington Disease. Am J Hum Genet 1999;64:1293-304.